Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Experimental drug may reduce lymphedema swelling and scarring (opens in a new tab)

medicalxpress.com · 2026-09-30

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 5Not checkedStanford Medicine researchers completed a clinical trial in which 23 volunteers with lower-limb lymphedema took acebilustat once daily for a year.View evidenceHide evidence

As stated23 volunteers; once daily for a year

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 5Not checkedThe article says acebilustat effectively alleviated many of the disease's most burdensome symptoms and may be even more powerful against lymphedema's effects than ketoprofen was.View evidenceHide evidence

As statedan average of one liter of volume from affected legs

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 5Not checkedPatients in the trial reportedly lost an average of one liter of volume from their affected legs, and their skin thickness, scarring, and quality of life improved.View evidenceHide evidence

As statedaverage of one liter

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 5Not checkedThe story says the study was published in Scientific Reports and names Catharine Bowman as lead author and Stanley Rockson as senior author.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 5Not checkedThe article notes that a placebo-controlled phase 2 trial of acebilustat for upper-limb lymphedema is underway in analysis, and that a successful next step would be an international phase 3 trial aimed at FDA approval.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Therapeutic selective leukotriene b4 antagonism for human lymphedema

Scientific Reports · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

And 10 more candidates considered.